Deadly Liver Mob: Engaging Aboriginal People In Viral Hepatitis, HIV And Sexual Health Services
Funder
National Health and Medical Research Council
Funding Amount
$848,441.00
Summary
Rates of blood-borne viruses and sexually transmissible infections are high among the Aboriginal and Torres Strait Islander population. A local initiative in western Sydney has trialed a new approach to engagement and care of Aboriginal people. We will implement this approach in services across NSW and evaluate its effectiveness as a sustainable and acceptable model for engaging Aboriginal people in care and develop an implementation plan for future roll-out to other services.
A Novel Hepatitis B Virus Genotype In Indigenous Australians: Impact On Vaccine Efficacy And Clinical Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$1,100,960.00
Summary
We have recently identified a novel Hepatitis B virus (HBV) genotype (C4) circulating in Northern Territory (NT) Indigenous communities. Concurrently, epidemiological studies suggest that the HBV vaccine may not be working well and that there are high rates of liver cancer due to HBV in these communities. Our project will determine if HBV/C4 is linked to poor vaccine responses and accelerated liver disease, with implications for HBV vaccine strategy and clinical management of HBV/C4 infections.
SCALE-C: Strategies For Hepatitis C Testing And Treatment In Aboriginal Communities That Lead To Elimination
Funder
National Health and Medical Research Council
Funding Amount
$2,175,170.00
Summary
Prevalence of hepatitis C infection within the Aboriginal population is among the highest of any identifiable population in Australia. Highly effective, direct-acting antiviral (DAA) therapy, and their listing on the PBS in 2016 has revolutionised HCV clinical management in Australia. The SCALE-C study will evaluate an established test and treat model to rapidly scale-up DAA within four Aboriginal communities to determine both impact on community prevalence and ongoing transmission.
Randomised Controlled Trial Of Azithromycin To Reduce The Morbidity Of Severe Bronchiolitis In Indigenous Infants
Funder
National Health and Medical Research Council
Funding Amount
$1,456,802.00
Summary
Acute lower respiratory infections are the commonest cause of hospitalisations and retrievals from remote communities. Early severe respiratory infections likely impair lung growth. We will examine whether azithromycin (antibiotic with anti-inflammatory properties) should be used to treat infants hospitalised with bronchiolitis to reduce the severity of bronchiolitis and prevent rehospitalisation. The study potentially improves acute clinical care as well as prevents future respiratory illness.